In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 275 of 404

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
OrganOx metra for liver transplant [ID5116]	Technology appraisal guidance	TBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]	Technology appraisal guidance	TBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]	Technology appraisal guidance	20 August 2025
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]	Technology appraisal guidance	TBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)	NICE guideline	TBC
Ovarian cancer QS update	Quality standard	5 February 2025
Overweight and obesity management	NICE guideline	TBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]	Technology appraisal guidance	TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]	Technology appraisal guidance	TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]	Technology appraisal guidance	TBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]	Technology appraisal guidance	16 July 2025
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]	Highly specialised technology	TBC
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]	Highly specialised technology	TBC
Peezy Midstream for urine collection (MT446)	Medical technologies guidance	TBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594	Technology appraisal guidance	TBC
Pegcetacoplan for treating geographic atrophy [ID4041]	Technology appraisal guidance	TBC
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]	Technology appraisal guidance	TBC
Pegzilarginase for treating arginase-1 deficiency [ID4029]	Highly specialised technology	TBC
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473	Technology appraisal guidance	TBC
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]	Technology appraisal guidance	11 December 2024
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]	Technology appraisal guidance	TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]	Technology appraisal guidance	TBC

Results per page

10
25
50
All